March 31, 2010 — A blood test may soon be able to identify which patients with multiple sclerosis will and will not respond to beta interferon. Only a reported two-thirds of patients with ...

NEW YORK (Reuters Health) - Early treatment of multiple sclerosis (MS) patients with interferon beta-1b therapy may help slow down the onset of disability, according to a report in this week's issue ...

Please provide your email address to receive an email when new articles are posted on . Researchers compared data from those treated in the phase 3 EVOLVE-MS-1 and DECIDE studies. Treatment with ...

October 24, 2011 (Amsterdam, the Netherlands) — The full results of a phase 3 trial directly comparing alemtuzumab (Lemtrada, Genzyme) with interferon-beta-1a (Rebif, EMD Serono/Pfizer) show a ...

A study published in this week’s issue of THE LANCET suggests that high-dose interferon beta-1b administered every other day is more effective than interferon beta-1a once a week for people with ...

Specialists in neuroimaging at UB have proposed a mechanism by which interferon beta-1a may limit brain atrophy in multiple sclerosis (MS) patients. The positive effect of interferon beta-1a, a ...

Drugs called interferon betas are common treatments for multiple sclerosis (MS), reducing relapses and slowing motor function decline. Interferon beta, a protein known to contain a zinc binding pocket ...

Drugs called interferon betas are common treatments for multiple sclerosis (MS), reducing relapses and slowing motor function decline. Interferon beta, a protein known to contain a zinc binding pocket ...

Disease activity despite interferon predicts poor MS outcomes In relapsing-remitting MS, disease activity after treatment with interferon (IFN)β-1a linked to poor long-term outcomes. HealthDay News — ...

How Does Ocrevus or Ocrevus Zunovo Work in MS? MS happens when your immune system damages the protective covering around the nerves in your brain, called myelin. This affects how your brain ...